Top

Journal of Endocrinological Investigation

Open Access 29-04-2024 | Hypothyroidism | Original Article

Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study

Authors: M. Albertelli, G. Rossi, E. Nazzari, C. Genova, F. Biello, E. Rijavec, M. G. Dal Bello, L. Patti, M. Tagliamento, G. Barletta, P. Morabito, M. Boschetti, A. Dotto, D. Campana, D. Ferone, F. Grossi

Published in: Journal of Endocrinological Investigation

Abstract

Purpose

Immune checkpoint inhibitors (ICPIs) disrupting PD-1/PD-L1 axis have revolutionized the management of advanced non-small cell lung cancer (NSCLC). Some studies identified the development of endocrine toxicity as predictor of better survival in cancer patients treated with ICPIs. The aim of study was to evaluate survival and new onset of immune-related endocrine adverse events (irAEs) in patients treated with nivolumab for advanced NSCLC.

Methods

In a prospective study, 73 patients with previously treated advanced NSCLC received nivolumab in monotherapy. Blood samples were collected at each cycle to monitor thyroid autoimmunity, thyroid, adrenal and somatotroph axes, while thyroid morphology was evaluated by ultrasonography.

Results

An impaired thyroid function was recorded in 23.4% of patients (n = 15). Eight patients developed asymptomatic transient thyrotoxicosis (ATT) evolving to hypothyroidism in 50% of cases. In addition, seven patients developed overt hypothyroidism without ATT and with negative autoantibodies. Patients who developed hypothyroidism proved to have better overall survival (OS) as compared with non-developers at both univariate (p = 0.021) and multivariate analyses (p = 0.023). The survival curve of patients with reduced IGF-I at baseline, or displaying its reduction during the follow-up, showed significantly reduced median survival compared to patients with normal/high IGF-I levels (p = 0.031).

Conclusions

Thyroid function abnormalities are the major irAEs in patients treated with nivolumab, and hypothyroidism onset is associated with prolonged survival. Our findings indicate that the development of hypothyroidism is a positive predictive biomarker of nivolumab antitumor efficacy in patients with NSCLC. Low IGF-I levels could represent a negative prognostic factor during nivolumab therapy.

Cheung YM, Wang W, McGregor B et al (2022) Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother 71(8):1795–1812. https://doi.org/10.1007/s00262-021-03128-7CrossRefPubMedPubMedCentral

De Miguel M, Calvo E (2020) Clinical challenges of immune checkpoint inhibitors. Cancer Cell 38(3):326–333. https://doi.org/10.1016/j.ccell.2020.07.004CrossRefPubMed

Albertelli M, Dotto A, Nista F et al (2021) Present and future of immunotherapy in neuroendocrine tumors. Rev Endocr Metab Disord 22(3):615–636. https://doi.org/10.1007/s11154-021-09647-zCrossRefPubMedPubMedCentral

Melosky B, Juergens R, Hirsh V et al (2020) Amplifying outcomes: checkpoint inhibitor combinations in first-line non-small cell lung cancer. Oncologist 25(1):64–77. https://doi.org/10.1634/theoncologist.2019-0027CrossRefPubMed

Fanciulli G, Di Molfetta S, Dotto A et al (2020) Emerging therapies in pheochromocytoma and paraganglioma: immune checkpoint inhibitors in the starting blocks. J Clin Med 10(1):88. https://doi.org/10.3390/jcm10010088CrossRefPubMedPubMedCentral

Di Molfetta S, Dotto A, Fanciulli G et al (2021) Immune checkpoint inhibitors: new weapons against medullary thyroid cancer? Front Endocrinol (Lausanne) 12:667784. https://doi.org/10.3389/fendo.2021.667784CrossRefPubMed

FDA prescribing information (2018). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s058lbl.pdf Accessed 19 May 2021

Guo L, Zhang H, Chen B (2017) Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer 8(3):410–416. https://doi.org/10.7150/jca.17144CrossRefPubMedPubMedCentral

Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643CrossRefPubMedPubMedCentral

10.

Brahmer J, Reckamp KL, Baas P et al (2013) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627CrossRef

11.

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. https://doi.org/10.1056/NEJMoa1003466CrossRefPubMedPubMedCentral

12.

Ryder M, Callahan M, Postow MA, Wolchok J, Fagin AJ (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Related Cancer 21(2):371–381. https://doi.org/10.1530/ERC-13-0499CrossRef

13.

Barroso-Sousa R, Barry WT, Garrido-Castro AC et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4(2):173–182. https://doi.org/10.1001/jamaoncol.2017.3064CrossRefPubMed

14.

Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583–589. https://doi.org/10.1093/annonc/mdw640CrossRefPubMed

15.

Kotwal A, Kottschade L, Ryder M (2020) PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid 30(2):177–184. https://doi.org/10.1089/thy.2019.0250CrossRefPubMedPubMedCentral

16.

Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Endocrinol Metab 33(7):773–781. https://doi.org/10.1200/JCO.2014.57.4756CrossRef

17.

Haratani K, Hayashi H, Chiba Y et al (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4(3):374–378. https://doi.org/10.1001/jamaoncol.2017.2925CrossRefPubMed

18.

Masuda K, Shoji H, Nagashima K et al (2019) Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer 19(1):974. https://doi.org/10.1186/s12885-019-6150-yCrossRefPubMedPubMedCentral

19.

Ricciuti B, Genova C, De Giglio A et al (2019) Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 145(2):479–485. https://doi.org/10.1007/s00432-018-2805-3CrossRefPubMed

20.

Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133. https://doi.org/10.1089/thy.2015.0020CrossRefPubMedPubMedCentral

21.

Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F (2013) Endocrine side effetcs induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98(4):1361–1375. https://doi.org/10.1210/jc.2012-4075CrossRefPubMed

22.

Weber JS, Hodi FS, Wolchok JD et al (2017) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35(7):785–792. https://doi.org/10.1200/JCO.2015.66.1389CrossRefPubMed

23.

De Velasco G, Je Y, Bossé D et al (2017) Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res 5(4):312–318. https://doi.org/10.1158/2326-6066CrossRefPubMedPubMedCentral

24.

Kumar V, Ghaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017) Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8:49. https://doi.org/10.3389/fphar.2017.00049CrossRefPubMedPubMedCentral

25.

Ramos-Levi AM, Rogado J, Sanchez-Torres JM, Colomer R, Marazuela M (2018) Nivolumab-induced thyroid dysfunction in patients with lung cancer. Endocrinol Diabetes Nutrición 66(1):26–34. https://doi.org/10.1016/j.endinu.2018.05.005CrossRef

26.

Brilli L, Danielli R, Ciuoli C et al (2018) Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine 58(3):534–541. https://doi.org/10.1007/s12020-017-1289-2CrossRef

27.

Illouz F, Drui D, Caron P, Do Cao C (2018) Expert opinion on thyroid complications in immunotherapy. Ann Endocrinol (Paris) 79(5):555–561. https://doi.org/10.1016/j.ando.2018.07.007. (Epub 2018 Jul 25)CrossRefPubMed

28.

Yamauchi I, Sakane Y, Fukuda Y et al (2017) Clinical features of nivolumab-induced thyroiditis: a case series study. Thyroid 27(7):849–901. https://doi.org/10.1089/thy.2016.0562CrossRef

29.

Kitajima K, Ashida K, Wada N et al (2017) Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab. Jpn J Clin Oncol 47(5):463–466. https://doi.org/10.1093/jjco/hyx018CrossRefPubMed

30.

Takaya K, Sonoda M, Fuchigami A, Hiyoshi T (2017) Isolated adrenocorticotropic hormone deficiency caused by nivolumab in a patient with metastatic lung cancer. Intern Med 56(18):2463–2469. https://doi.org/10.2169/internalmedicine.8548-16CrossRefPubMedPubMedCentral

31.

Zeng MF, Chen LL, Ye HY et al (2017) Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: case report and review. Medicine 96(44):e8426. https://doi.org/10.1097/MD.0000000000008426CrossRefPubMedPubMedCentral

32.

Ariyasu H, Inaba H, Ota T et al (2018) Thyrotoxicosis and adrenocortical hormone deficiency during immune-checkpoint inhibitor treatment for malignant melanoma. In Vivo 32(2):345–351. https://doi.org/10.21873/invivo.11244CrossRefPubMedPubMedCentral

33.

Kitano S, Tatsuno K, Ishibe J et al (2018) Isolated adrenocorticotropic hormone deficiency in melanoma patients treated with nivolumab. Acta Derm Venereol 98(7):704–705. https://doi.org/10.2340/00015555-2902CrossRefPubMed

34.

Takebayashi K, Ujiie A, Kubo M et al (2018) Isolated adrenocorticotropic hormone deficiency and severe hypercalcemia after destructive thyroiditis in a patient on nivolumab therapy with a malignant melanoma. J Clin Med Res 10(4):358–362. https://doi.org/10.14740/jocmr3257wCrossRefPubMedPubMedCentral

35.

Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91(2):151–156 ((PMID: 9923856))CrossRefPubMed

36.

Spitz MR, Barnett MJ, Goodman GE, Thornuist MD, Wu X, Pollak M (2002) Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomark Prev 11(11):1413–1418 ((PMID:12433720))

37.

Wang Z, Wang Z, Liang Z et al (2013) Expression and clinical significance of IGF-1, IGFBP-3, and IGFBP-7 in serum and lung cancer tissues from patients with non-small cell lung cancer. OncoTargets Ther 6:1437–1444. https://doi.org/10.2147/OTT.S51997CrossRef

38.

Gao Y, Katki H, Graubard B et al (2012) Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. Int J Cancer 131(2):105–113. https://doi.org/10.1002/ijc.26438CrossRef

39.

Christopoulos PF, Msaouel P, Koutsilieris M (2015) The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer 14:43. https://doi.org/10.1186/s12943-015-0291-7CrossRefPubMedPubMedCentral

40.

Zhang M, Li X, Zhang X, Yang Y, Feng Z, Liu X (2014) Association of serum hemoglobin A1c, C-peptide and insulin-like growth factor-1 levels with the occurrence and development of lung cancer. Mol Clin Oncol 2($):506–508. https://doi.org/10.3892/mco.2014.289CrossRefPubMedPubMedCentral

41.

Boschetti M, Larizza D, Calcaterra V et al (2009) Effect of environment on growth: auxological and hormonal parameters in African and Italian children. Growth Horm IGF Res 19(3):238–241. https://doi.org/10.1016/j.ghir.2008.10.005CrossRefPubMed

42.

Heald AH, Sharma R, Anderson SG et al (2005) Dietary intake and the insulin-like growth factor system: effects of migration in two related populations in India and Britain with markedly different dietary intake. Public Health Nutr 8(6):620–627. https://doi.org/10.1079/PHN2005729CrossRefPubMed

43.

Peters S, Cappuzzo F, Horn L et al (2017) Analysis of early survival in patients with advanced non-squamous NSCLC treated with nivolumab vs docetaxel in checkmate 057. J Thorac Oncol 12(1):S253. https://doi.org/10.1016/j.jtho.2016.11.241CrossRef

44.

Tas F, Karabulut S, Bilgin E, Tastekin D, Duranyildiz D (2014) Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer. Tumour Biol 35(9):9303–9309. https://doi.org/10.1007/s13277-014-2224-2CrossRefPubMed

45.

Feng X, Lin J, Xing S, Liu W, Zhang G (2017) Higher IGFBP-1 to IGF-1 serum ratio predicts unfavourable survival in patients with nasopharyngeal carcinoma. BMC Cancer 17(1):90. https://doi.org/10.1186/s12885-017-3068-0CrossRefPubMedPubMedCentral

46.

Yao Y, Mao W, Dong M, Yang D, Li W, Chen Y (2017) Serum insulin-like growth factor-1 (IGF-1): a novel prognostic factor for early recurrence of hepatocellular carcinoma (HCC). Clin Lab 63(2):261–270. https://doi.org/10.7754/Clin.Lab.2016.160732CrossRefPubMed

47.

Zhao Z, Wang X, Qu J et al (2021) Immune-related adverse events associated with outcomes in patients with NSCLC treated with anti-PD-1 Inhibitors: a systematic review and meta-analysis. Front Oncol 11:708195. https://doi.org/10.3389/fonc.2021.708195CrossRefPubMedPubMedCentral

48.

Yamauchi I, Yasoda A, Matsumoto S et al (2019) Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS ONE 14(5):e0216954. https://doi.org/10.1371/journal.pone.0216954CrossRefPubMedPubMedCentral

49.

Baldini E, Lunghi A, Cortesi E et al (2020) Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. Lung Cancer 140:59–64. https://doi.org/10.1016/j.lungcan.2019.12.014CrossRefPubMed

50.

Campredon P, Mouly C, Lusque A et al (2019) Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients. Presse Med 48(4):e199–e207. https://doi.org/10.1016/j.lpm.2018.10.019CrossRefPubMed

51.

Sbardella E, Tenuta M, Sirgiovanni G et al (2019) Thyroid disorders in programmed death-1 inhibitors treated patients: is previous therapy with tyrosine Kinase Inhibitors a predisposing factor? Clin Endocrinol (Oxford) 92(3):258–265. https://doi.org/10.1111/cen.14135CrossRef

52.

Ksienski D, Wai ES, Croteau N, Lesperance M et al (2019) Efficacy of Nivolumab and Pembrolizumab in patients with advanced non-small-cell lung cancer needing treatment interruption because of adverse events: a retrospective multicenter analysis. Clin Lung Cancer 20(1):e97–e106. https://doi.org/10.1016/j.cllc.2018.09.005CrossRefPubMed

53.

Peiró I, Palmero R, Iglesias P et al (2019) Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. Endocrine 64(3):605–613. https://doi.org/10.1007/s12020-019-01871-7CrossRefPubMed

54.

Barlesi F, Dixmier A, Debieuvre D et al (2020) Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study. Oncoimmunology 9(1):1744898. https://doi.org/10.1080/2162402X.2020.1744898CrossRefPubMedPubMedCentral

55.

Hosoya K, Fujimoto D, Morimoto T et al (2020) Association between early immune-related adverse events and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Clin Lung Cancer 21(4):e315–e328. https://doi.org/10.1016/j.cllc.2020.01.003CrossRefPubMed

56.

Sato K, Akamatsu H, Murakami E et al (2018) Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115:71–74. https://doi.org/10.1016/j.lungcan.2017.11.019CrossRefPubMed

57.

Kim HI, Kim M, Lee SH et al (2017) Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. Oncoimmunology 7(1):e1375642. https://doi.org/10.1080/2162402X.2017.1375642CrossRefPubMedPubMedCentral

Title: Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study
Authors: M. Albertelli
G. Rossi
E. Nazzari
C. Genova
F. Biello
E. Rijavec
M. G. Dal Bello
L. Patti
M. Tagliamento
G. Barletta
P. Morabito
M. Boschetti
A. Dotto
D. Campana
D. Ferone
F. Grossi
Publication date: 29-04-2024
Publisher: Springer International Publishing
Keywords: Hypothyroidism
NSCLC
NSCLC
Thyrotoxicosis
Checkpoint Inhibitors
Published in: Journal of Endocrinological Investigation
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-023-02268-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com